Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.

We also observed a positive trend between free Debio 1143 concentrations in tumor tissue and CD‐positive cell ratio relative change from baseline, in line with the immunomodulatory properties of Debio 1143 described previously.

also in 11,005 other papers

We did not observe a significant trend in the degradation of cIAP‐1 in the combination or cisplatin alone cohorts (Figure S2 ) and we did not observe a significant trend in the degradation of cIAP‐2 (Figure S3 ) or XIAP (data not shown) in any of the treatment cohorts.

also in 9,775 other papers